Part D plan preference for higher-cost hepatitis C drugs led to higher Medicare and beneficiary spending
On August 11, the OIG published a review of the utilization of hepatitis C drugs in Medicare Part D compared to utilization of the same drugs in Medicaid in 2019 and 2020. The review was conducted because preliminary research indicated that Part D beneficiaries were using higher-cost hepatitis C drugs rather than the generic versions that were increasingly being used by Medicaid beneficiaries.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.